Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic
parenchymal injury, persistent activation of inflammatory response as well as sustained …

Liver metastasis of colorectal cancer (CRLM) is the most common cause of CRC‐related
mortality, and is typically caused by interactions between CRC cells and the tumour …

The tumour microenvironment, also termed the tumour stroma or tumour mesenchyme,
includes fibroblasts, immune cells, blood vessels and the extracellular matrix and …

Hepatic fibrosis is a dynamic process characterized by the net accumulation of extracellular
matrix resulting from chronic liver injury of any aetiology, including viral infection, alcoholic …

Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more
than one million deaths annually via development of cirrhosis, although no antifibrotic …

Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

Liver cancer is the second leading cause of cancer mortality worldwide, causing more than
700,000 deaths annually. Because of the wide landscape of genomic alterations and limited …

Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and lacks
effective therapeutic approaches. Most HCC develops in the setting of chronic liver injury …